August 4, 2023—S4 Medical Corp, which is developing an esophageal deflection device to use during atrial fibrillation (AF) ablation procedures, recently announced the closing of a $5 million investment as part of its Series B financing round. The financing will support the United States and European regulatory approval of the company’s Esolution device as well as manufacturing scale-up for potential commercial launch in 2024. The financing, which was led by a multinational strategic corporation, includes an option to buy the company upon completion of certain milestones.
According to S4 Medical, the company’s device is designed to use suction and deflection to deviate the esophagus away from ablation energy used in AF ablation procedures. Use of the device showed significant reduction in ablation-related esophageal injury in EASY AF, the company’s recent randomized, prospective, multicenter, multinational, and double-blinded investigational device exemption study.